Nektar Therapeutics (NKTR)

Company Description

Nektar Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to improve the benefits of drugs for patients. Its product pipeline consists of drug candidates across a number of therapeutic areas, including oncology, pain, anti-infectives, anti-viral and immunology. Nektar’s research and development activities involve small molecule drugs, peptides and other potential biologic drug candidates. Its drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient.

 

COMPANY ADDRESS
455 Mission Bay Boulevard South
San Francisco, California 94158
United States

COMPANY PHONE
415-482-5300

COMPANY WEBSITE



Get BioInvest's perspective on Nektar Therapeutic's CEO


Latest Company News

Nektar Therapeutics' (NKTR) "Overweight" Rating Reaffirmed at Piper Jaffray ... The Cerbat Gem - 14 minutes ago Nektar Therapeutics logo Piper Jaffray Companies reaffirmed their overweight rating on shares of Nektar Therapeutics (NASDAQ:NKTR) in a research report released on Tuesday. They currently have a $29.00 price target on the biopharmaceutical company's ... Nektar Therapeutics (NKTR) Given Daily News Sentiment Score of 0.11 - Markets Daily Crazy Volume Spikes for: Nektar Therapeutics (NKTR) - HugoPress [...]
Fri, Apr 28, 2017 6:11:00 AM, Continue reading at the source
Trading Options: Nektar Therapeutics (NASDAQ:NKTR) : Covered Calls With ... CML News - 5 hours ago While covered calls are one of the most commonly used option strategies, it turns out we need to be clever in how we treat earnings in order to maximize the strategy in Nektar Therapeutics (NASDAQ:NKTR) . Even further, if we don't do this analysis, we ... [...]
Fri, Apr 28, 2017 1:07:00 AM, Continue reading at the source
Trading Focus on Shares of Nektar Therapeutics (NASDAQ:NKTR) Rives Journal - 11 hours ago Checking the Value Composite score for Nektar Therapeutics (NASDAQ:NKTR), we see that the company has a rank of 89. This falls on a scale from 0 to 100 where a lower score indicated an undervalued company and a higher score would indicate an ... [...]
Thu, Apr 27, 2017 7:18:00 PM, Continue reading at the source
Nektar Therapeutics (NKTR) Director Sells $140350.00 in Stock The Cerbat Gem - 22 hours ago Nektar Therapeutics logo Nektar Therapeutics (NASDAQ:NKTR) Director Lutz Lingnau sold 7,000 shares of Nektar Therapeutics stock in a transaction dated Friday, April 7th. The shares were sold at an average price of $20.05, for a total value of $140,350.00. Nektar Therapeutics (NKTR): Notes From The Road - Jefferies - StreetInsider.com Nektar Therapeutics (NKTR) EPS Estimated At $-0.40; AutoZone, Inc. (AZO) Had 9 ... - HuronReport [...]
Thu, Apr 27, 2017 7:30:00 AM, Continue reading at the source
Nektar Therapeutics (NKTR): From Top to Bottom StockNewsJournal - Apr 21, 2017 Nektar Therapeutics (NKTR) is an interesting player in the Healthcare space, with a focus on Biotechnology. The stock has been active on the tape, currently trading at $19.13, up from yesterday's close by 2.79%. Mallinckrodt Public Limited Company versus Nektar Therapeutics Head to Head ... - CML News Thrivent Financial for Lutherans Raises Position in Nektar Therapeutics (NKTR) - The Cerbat Gem [...]
Fri, Apr 21, 2017 7:18:00 PM, Continue reading at the source
Today's Research Reports on Biotech Stocks to Watch: Nektar Therapeutics and ... Yahoo Finance - Apr 10, 2017 NEW YORK, NY / ACCESSWIRE / April 10, 2017 / The iShares NASDAQ Biotechnology Index ETF gained 0.80 percent to close at 290.52, up 9.47 percent year-to-date. Nektar Therapeutics (NKTR) Plunges 8.01% on April 10 - Equities.com A Keen Look At The Chart For Nektar Therapeutics (NKTR) - NY Stock News [...]
Mon, Apr 10, 2017 1:43:00 PM, Continue reading at the source
Nektar Therapeutics (NKTR) Up 57.2% Since Earnings Report: Can It Continue? Yahoo Finance - Apr 7, 2017 It has been about a month since the last earnings report for Nektar Therapeutics NKTR. Shares have added about 57.2% in that time frame, outperforming the market. Nektar Therapeutics Presents New Preclinical Data for its Immuno-Oncology ... - PR Newswire (press release) The Zacks Analyst Blog Highlights: Esperion Therapeutics, Vertex ... - Nasdaq [...]
Fri, Apr 07, 2017 11:54:00 AM, Continue reading at the source
A Quick Evaluation Of Nektar Therapeutics' PEGylation Platform Seeking Alpha - Apr 5, 2017 PEGylation or Polymer Conjugation is the proprietary technology of Nektar Therapeutics (NASDAQ:NKTR). Polymer drug conjugates provide an efficient targeted therapy for a wide range of diseases. [...]
Wed, Apr 05, 2017 4:36:00 PM, Continue reading at the source
BRIEF-Nektar Therapeutics presents new preclinical data for its immuno ... Reuters - Apr 4, 2017 NEW YORK, April 4 More companies, including carmaker BMW and insurer Allstate, have pulled their advertising from Fox News' "The O'Reilly Factor" television program days after the New York Times reported Fox and star host Bill O'Reilly paid five women ... [...]
Tue, Apr 04, 2017 1:23:00 PM, Continue reading at the source
Western Digital, Nektar Therapeutics And Two More Stocks Breaking Out Forbes - Mar 30, 2017 These four stocks, two of them biotechs and two technology, have strong technical momentum. Cara Therapeutics Inc. (CARA) had a nice follow-through on Tuesday, jumping 94 cents, or 5%, to $19.09, on 7.6 million shares. [...]
Thu, Mar 30, 2017 1:24:00 PM, Continue reading at the source